Employees: 2,843
Size Sihuan Pharmaceutical (0460.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $856M, the 617th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$0.73 on 18 Nov 2026.
Performance Over six months the shares fell 33.8%, against -18.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 29.7% over the last twelve months (peer median +1.8%); the operating margin is 14.5% (peer median 12.2%).
Valuation It trades at 8.7× forward earnings against a peer median of 21.4× (2nd cheapest of 16).
Capital Return on invested capital runs 3.6 points below its cost of capital (8.4% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.94B | HK$2.84B | HK$2.06B | HK$2.06B | HK$2.54B |
| Revenue growth | — | +38% | 0% | -19% | — |
| Gross profit | HK$1.92B | HK$1.90B | HK$1.27B | HK$1.35B | HK$1.62B |
| EBITDA | HK$662M | HK$658M | -HK$175M | HK$26.2M | -HK$129M |
| Net income | HK$341M | HK$195M | -HK$235M | -HK$59.7M | -HK$2.27B |
| Free cash flow | -HK$108M | -HK$47.3M | HK$301M | HK$199M | -HK$306M |
| Capital expenditure | HK$265M | HK$211M | HK$202M | HK$326M | HK$691M |
| Total debt | n/a | HK$1.12B | HK$1.04B | HK$1.40B | HK$1.47B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0460.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.8% | -9.2% | 4th highest of 21 |
| 6-month return | -33.8% | -18.4% | 4th lowest of 21 |
| Distance from 52-week high | -58.9% | -39.3% | lowest of 21 |
| Revenue growth (TTM) | +29.7% | +1.8% | 5th highest of 21 |
| Operating margin | 14.5% | 12.2% | 9th highest of 21 |
| Forward P/E | 8.7× | 21.4× | 2nd cheapest of 16 |
| ROIC minus cost of capital | -3.6 pp | +1.2 pp | 5th lowest of 21 |
| EV / EBITDA | 9.2× | 18.9× | cheapest of 8 |
| Net debt / EBITDA | -2.3× | -1.1× | 4th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $856M | -34% | +30% | 15% | 8.7× | n/a | n/a |
| TSI 603262.SS | China | $842M | -46% | +3% | 14% | 47.7× | 24.3% | +13.4% |
| PharmaNutra PHN.MI | Italy | $922M | +2% | +17% | 22% | 33.5× | 4.7% | +18.5% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $942M | -18% | -14% | 8% | 182.0× | n/a | n/a |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $760M | -8% | -18% | 25% | 7.6× | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $759M | -6% | -9% | 1% | 16.2× | 14.1% | +15.6% |
| Applied Nutrition APN.L | United Kingdom | $986M | +31% | +51% | 25% | 21.4× | 24.6% | +38.5% |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.01B | -17% | -5% | 4% | 20.0× | 0.5% | +7.9% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $718M | -36% | -12% | 3% | n/a | 2.1% | -1.3% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $703M | -20% | -14% | 22% | n/a | 0.4% | +4.8% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.05B | -12% | -3% | 24% | 12.8× | -8.7% | +5.5% |
| Brother Enterprises 002562.SZ | China | $668M | -33% | +8% | 4% | n/a | 4.0% | +13.5% |
| HBM 2142.HK | Hong Kong | $1.12B | -18% | +55% | 44% | 11.7× | 13.1% | +62.3% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $641M | -22% | -28% | -25% | n/a | n/a | n/a |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $613M | -30% | 0% | 0% | n/a | n/a | n/a |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| ABA Chemicals 300261.SZ | China | $592M | -26% | -16% | -23% | 405.0× | n/a | n/a |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $583M | -23% | +21% | 11% | 45.4× | 19.1% | +12.1% |